Tiny infants get new hope in malaria fight
NCT ID NCT04300309
Summary
This study tested a new, dissolvable tablet version of a common malaria medicine (artemether-lumefantrine) for the smallest patients: newborns and infants weighing less than 11 pounds. Researchers wanted to see if the right amount of medicine got into babies' bodies, if it was safe and well-tolerated, and if it effectively cleared the malaria parasite. The trial included two groups of very young babies to find the best dose.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PLASMODIUM FALCIPARUM MALARIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Novartis Investigative Site
Nanoro, Burkina Faso
-
Novartis Investigative Site
Ouagadougou, Burkina Faso
-
Novartis Investigative Site
Kisantu, Bas Kongo, Democratic Republic of the Congo
Conditions
Explore the condition pages connected to this study.